Assess the Effectiveness of Atomoxetine in Children With Fetal Alcohol Syndrome and ADD/ADHD - Full Text View

Purpose

The purpose of this study is to determine if atomoxetine hydrochloride improves inattention, hyperactivity, and impulsivity problems in children exposed to alcohol during birth.

Condition	Intervention	Phase
Fetal Alcohol Syndrome Attention Deficit Disorder With Hyperactivity (ADHD) Attention Deficit Disorder (ADD)	Drug: Strattera Drug: Placebo	Phase 3

Study Type:	Interventional
Study Design:	Allocation: Randomized Endpoint Classification: Safety/Efficacy Study Intervention Model: Crossover Assignment Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor) Primary Purpose: Treatment
Official Title:	A Study of the Efficacy of Atomoxetine in Treating the Inattention, Impulsivity and Hyperactivity in Children With Fetal Alcohol Syndrome or Effects

Resource links provided by NLM:

MedlinePlus related topics: Attention Deficit Hyperactivity Disorder Fetal Alcohol Spectrum Disorders

Drug Information available for: Atomoxetine hydrochloride Atomoxetine

U.S. FDA Resources

Further study details as provided by University of Oklahoma:

Primary Outcome Measures:

ADHD Rating Scale - IV [ Time Frame: length of protocol ] [ Designated as safety issue: No ]

Secondary Outcome Measures:

Determine if atomoxetine is safe and well tolerated by children with FAS. [ Time Frame: length of protocol ] [ Designated as safety issue: Yes ]
Determine if atomoxetine is effective in both school and home, and significantly reduces symptoms of inattention, hyperactivity, and impulsivity in children with FAS compared to children with FAS receiving placebo. [ Time Frame: length of protocol ] [ Designated as safety issue: No ]
Determine if atomoxetine improves behaviors in the mornings and evenings. [ Time Frame: Length of protocol ] [ Designated as safety issue: No ]
Determine if parents of children with FAS are satisfied with the effectiveness of atomoxetine. [ Time Frame: Length of protocol ] [ Designated as safety issue: No ]
Determine if there are any differences in the adverse effects profile of children with FAS compared to the overall profile for atomoxetine. [ Time Frame: Length of protocol ] [ Designated as safety issue: Yes ]
Determine the degree of functional limitation experienced by this group of children with FAS and whether this impairment is decreased by treatment with atomoxetine as demonstrated by the Pediatric Evaluation of Disability Inventory (PEDI) [ Time Frame: Length of protocol ] [ Designated as safety issue: No ]

Estimated Enrollment:	60
Study Start Date:	June 2006
Estimated Study Completion Date:	June 2012
Estimated Primary Completion Date:	April 2012 (Final data collection date for primary outcome measure)

Arms	Assigned Interventions
Active Comparator: 1 Atomoxetine HCL (Strattera)	Drug: Strattera escalating dosage: 0.5 mg/kg, 1.0 mg/kg, and 1.4 mg/kg titrated up or down according to adverse effects to therapy Other Name: atomoxetine HCL
Placebo Comparator: 2	Drug: Placebo 0.25 mg/kg, 0.5 mg/kg, 1.0 mg/kg, or 1.4 mg/kg once each morning with breakfast.

Detailed Description:

Abnormalities of attention, function, and activity level in children exposed to alcohol in utero share similarities and differences to children who do not have alcohol exposure. Previous psychological studies have examined either core attention deficit hyperactivity disorder (ADHD)symptoms of hyperactivity, inattention, and impulsivity or hypothesized neuropsychological differences in children with fetal alcohol syndrome (FAS) and ADHD. Atomoxetine Hydrochloride is a non-stimulant medication used to treat ADHD. This study will determine if atomoxetine HCL significantly reduces symptoms of ADD/ADHD in children with fetal alcohol exposure.

Eligibility

Ages Eligible for Study:	4 Years to 11 Years
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

Patient must be between the ages of 4 and 11 years at the time of entry into the study.
Patients must meet diagnostic criteria for FASD
Patient must meet DSM-IV criteria for ADHD, any subtype and must have an ADHDRS-IV score of > or = to 90%ile for age and gender for either subtest or total score if greater than 5 years of age.
Patients who enter the study at visit 1 taking stimulant medication must be medication-free for at least 24 hours before visit 2.
History and physical exam must reveal no clinically significant abnormalities that would preclude safe participation in the study.
Patients must be able to swallow capsules.
Patients must be of a sufficient developmental level (~3 yrs) to participate in the study.
Patients and parents must be able to communicate effectively with the investigator and coordinator and be judged reliable to keep appointments and participate in data collection.
Teacher must agree to cooperate with the study. Children less than 6 years old must have completed a course of PCIT and still meet DSM-IV criteria for ADHD.

Exclusion Criteria:

Have received an in investigational medication in the past 30 days.
Are currently on a medication treatment that is effective (ADHDRS-IV score within 1 SD of average) and well tolerated.
Have significant current medical conditions that could be exacerbated or compromised by atomoxetine.
Have used MAOIs within one month prior to visit 2.
Patients with hypertension.
Patients with a previous diagnosis of bipolar disorder, psychosis, or autism spectrum disorder.
Patients taking anticonvulsants for seizure control.
Patients taking another psychotropic medication or health food supplements purported to have central nervous system activity within 5 half-lives of visit 2.
Patients with Tourette Disorder or any other neurological condition that would interfere with their ability to receive treatment or comply with monitoring.
Pubertal girls.

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00417794

Contacts

Contact: Lora D Tusing, BS, RN	405-271-5700 ext 45167	lora-tusing@ouhsc.edu
Contact: Brenda Schlinke, R.N.	405-271-5700 ext 45167	brenda-schlinke@ouhsc.edu

Locations

United States, Oklahoma
OU Child Study Center	Recruiting
Oklahoma City, Oklahoma, United States, 73117
Contact: Lora D Tusing, BS, RN 405-271-5700 ext 45167 lora-tusing@ouhsc.edu
Contact: Brenda Schlinke, RN 405-271-5700 ext 45167 brenda-schlinke@ouhsc.edu
Principal Investigator: Thomas M Lock, M.D.
Sub-Investigator: Mark L Wolraich, M.D.
Sub-Investigator: Laura J McGuinn, M.D.

Sponsors and Collaborators

University of Oklahoma

Mark L. Wolraich, M.D.

Eli Lilly and Company

Investigators

Principal Investigator:

Thomas M. Lock, M.D.

University of Oklahoma

More Information

No publications provided

Responsible Party:	University of Oklahoma
ClinicalTrials.gov Identifier:	NCT00417794 History of Changes
Other Study ID Numbers:	B4Z-MC-X017
Study First Received:	January 2, 2007
Last Updated:	February 6, 2012
Health Authority:	United States: Institutional Review Board

Keywords provided by University of Oklahoma:

attention deficit hyperactivity disorder
ADHD
fetal alcohol syndrome

FAS
FASD
atomoxetine hcl

Additional relevant MeSH terms:

Attention Deficit Disorder with Hyperactivity
Fetal Alcohol Syndrome
Hyperkinesis
Fetal Diseases
Pregnancy Complications
Alcohol-Induced Disorders
Alcohol-Related Disorders
Substance-Related Disorders
Attention Deficit and Disruptive Behavior Disorders
Mental Disorders Diagnosed in Childhood
Mental Disorders
Dyskinesias

Neurologic Manifestations
Nervous System Diseases
Signs and Symptoms
Atomoxetine
Adrenergic Uptake Inhibitors
Adrenergic Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Neurotransmitter Uptake Inhibitors
Physiological Effects of Drugs

ClinicalTrials.gov processed this record on May 21, 2013